Ann Gils

Ghent University Hospital — Belgium

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index522citations84works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(62), Microscopic Colitis(42), Immunodeficiency and Autoimmune Disorders(27), Celiac Disease Research and Management(13), Helicobacter pylori-related gastroenterology studies(11)

Publications84 total

Laparoscopic‐assisted ‘pull‐introducer technique’ for gastrostomy tube placement in small infants: A single‐centre experience
JPGN Reports·2025Open Access
Su438 THE EFFECT OF AGING ON INFLIXIMAB EXPOSURE AND RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
Gastroenterology·2021
238 VEDOLIZUMAB CONCENTRATIONS IN COLONIC MUCOSAL TISSUE OF ULCERATIVE COLITIS PATIENTS INVERSELY CORRELATE WITH THE SEVERITY OF INFLAMMATION
Gastroenterology·2020· 2 cited
Sa1897 DEVELOPMENT AND VALIDATION OF DRIED BLOOD SPOT SAMPLING AS A TOOL TO IDENTIFY THE BEST TIME POINT TO MEASURE PREDICTIVE USTEKINUMAB SERUM CONCENTRATIONS IN PATIENTS WITH CROHN'S DISEASE
Gastroenterology·2020
P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation
Journal of Crohn s and Colitis·2020· 2 citedOpen Access
P542 The effect of age on infliximab pharmacokinetics in patients with inflammatory bowel disease
Journal of Crohn s and Colitis·2020· 1 citedOpen Access
879 – Switching from Infliximab Originator to a Biosimilar Does Not Affect Pharmacokinetics, Immunogenicity and Efficacy in Pediatric Patients with Inflammatory Bowel Disease
Gastroenterology·2019Open Access
Mo1910 – Long-Term Clinical Efficacy of Ustekinumab in Refractory Crohn’s Disease: A Multi-Centre Belgian Cohort Study
Gastroenterology·2019· 1 cited
Tu1821 – Pharmacokinetic and Pharmacodynamic Evaluation of Radiological Healing in Crohn's Disease Patients Treated with Infliximab: A Tailorix Mre Substudy
Gastroenterology·2019
Golimumab Trough Levels Predict Mucosal Healing and Success of Dose Optimization: A Prospective Observational Study
The American Journal of Gastroenterology·2018
Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial
2018
Mo1880 - Ustekinumab Induces Limited Mucosal Healing after 6 Months in a Real-Life, Prospective Cohort of Patients with Refractory Crohn's Disease
Gastroenterology·2018· 2 cited
346 - in Anti-TNF Naïve Crohn's Disease Patients Low Adalimumab Serum Levels at Week 4 Provoke Immunogenicity and Influence Therapy Outcome
Gastroenterology·2018
Sa1704 - Infliximab and Vedolizumab Show a Different Effect on Clot Formation in Inflammatory Bowel Disease Patients
Gastroenterology·2018
Tu1868 - Infliximab Trough Levels after Induction Therapy: A Predictive Factor for Outcome in Pediatric Patients with Inflammatory Bowel Disease
Gastroenterology·2018
Mo1847 - Reactive Dose Escalation of Infliximab in Patients with Crohn's Disease in Tailorix Leads to Improved Outcomes
Gastroenterology·2018
Mo1865 - Ustekinumab Induces Clinical and Biological Remission in Biologic Refractory Crohn's Disease Patients: A Real World Belgian Cohort Study
Gastroenterology·2018
Mo1846 - Adaptive Dosing During Infliximab Induction Therapy can Improve Mucosal Healing Rates in Patients with Ulcerative Colitis
Gastroenterology·2018
Mo1841 - Infliximab Exposure Predicts Superior Endoscopic Outcomes in Patients with Active Crohn's Disease: Pharmacokineticpharmacodynamic Analysis of Tailorix
Gastroenterology·2018· 1 cited
Mo1836 - Vedolizumab Trough Levels at Week 6 Predict Endoscopic and Clinical Remission in Inflammatory Bowel Disease
Gastroenterology·2018· 2 cited
page 1 of 5Next →

Frequent Co-authors

Séverine Vermeire(44), Marc Ferrante(26), Niels Vande Casteele(21), Gert Van Assche(20), Vera Ballet(20), Paul Rutgeerts(14), Griet Compernolle(14), Gert A. Van Assche(14), Isabelle Cleynen(11), David Drobne(9), Maja Noman(8), Filip J. Baert(7), Peter Bossuyt(6), Bram Verstockt(6), P. Rutgeerts(5), Paul Rutgeerts(5), Miet Peeters(4), Wouter Van Moerkercke(4), Matthias Jürgens(4), Christine Breynaert(4)